Lowenstein PR - Search Results

1

Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.

Kadiyala P, Carney SV, Gauss JC, Garcia-Fabiani MB, Haase S, Alghamri MS, Núñez FJ, Liu Y, Yu M, Taher A, Nunez FM, Li D, Edwards MB, Kleer CG, Appelman H, Sun Y, Zhao L, Moon JJ, Schwendeman A, Lowenstein PR, Castro MG. Kadiyala P, et al. Among authors: lowenstein pr. J Clin Invest. 2021 Feb 15;131(4):e139542. doi: 10.1172/JCI139542. J Clin Invest. 2021. PMID: 33332283 Free PMC article.

2

Antibodies to neuropeptide precursors expressed as fusion proteins in E. coli. Their use to examine neuropeptide biosynthetic pathways, intracellular trafficking and physiological activities.

Castro MG, Lowry PJ, Lowenstein PR. Castro MG, et al. Among authors: lowenstein pr. Int J Biochem. 1992 Jun;24(6):847-60. doi: 10.1016/0020-711x(92)90089-j. Int J Biochem. 1992. PMID: 1612176 Review. No abstract available.

3

Politically correct gene therapy? A "clean environment" improves gene delivery to the brain!

Lowenstein PR, Thomas CE, Castro MG. Lowenstein PR, et al. Gene Ther. 1999 Apr;6(4):463-4. doi: 10.1038/sj.gt.3300917. Gene Ther. 1999. PMID: 10476205 No abstract available.

4

Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo.

Gerdes CA, Castro MG, Löwenstein PR. Gerdes CA, et al. Among authors: lowenstein pr. Mol Ther. 2000 Oct;2(4):330-8. doi: 10.1006/mthe.2000.0140. Mol Ther. 2000. PMID: 11020348 Free article.

5

Death receptor-independent cytochrome c release and caspase activation mediate thymidine kinase plus ganciclovir-mediated cytotoxicity in LN-18 and LN-229 human malignant glioma cells.

Glaser T, Castro MG, Löwenstein PR, Weller M. Glaser T, et al. Among authors: lowenstein pr. Gene Ther. 2001 Mar;8(6):469-76. doi: 10.1038/sj.gt.3301415. Gene Ther. 2001. PMID: 11313826

6

Genetic engineering within the adult brain: implications for molecular approaches to behavioral neuroscience.

Lowenstein PR, Castro MG. Lowenstein PR, et al. Physiol Behav. 2001 Aug;73(5):833-9. doi: 10.1016/s0031-9384(01)00520-0. Physiol Behav. 2001. PMID: 11566216 Review.

7

Progress and challenges in viral vector-mediated gene transfer to the brain.

Lowenstein PR, Castro MG. Lowenstein PR, et al. Curr Opin Mol Ther. 2002 Aug;4(4):359-71. Curr Opin Mol Ther. 2002. PMID: 12222874

8

Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: peculiarities, mechanisms, and consequences.

Lowenstein PR, Castro MG. Lowenstein PR, et al. Gene Ther. 2003 Jun;10(11):946-54. doi: 10.1038/sj.gt.3302048. Gene Ther. 2003. PMID: 12756415 Review. No abstract available.

9

Recent advances in the pharmacology of neurological gene therapy.

Lowenstein PR, Castro MG. Lowenstein PR, et al. Curr Opin Pharmacol. 2004 Feb;4(1):91-7. doi: 10.1016/j.coph.2003.10.005. Curr Opin Pharmacol. 2004. PMID: 15018845 Free PMC article. Review.

10

Gene therapy and targeted toxins for glioma.

King GD, Curtin JF, Candolfi M, Kroeger K, Lowenstein PR, Castro MG. King GD, et al. Among authors: lowenstein pr. Curr Gene Ther. 2005 Dec;5(6):535-57. doi: 10.2174/156652305774964631. Curr Gene Ther. 2005. PMID: 16457645 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

339 results

Search Page